Q-omics provides the consensus-scored SPTBN5 profile across patient tissues and cancer cell-line models. SPTBN5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SPTBN5 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SPTBN5 RNA expression shows 17,218 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where SPTBN5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPTBN5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPTBN5 survival associations across molecular data types. SPTBN5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPTBN5 RNA expression–survival associations across cancer types. High SPTBN5 expression shows unfavorable associations in ACC, LGG and KIRC, but favorable associations in HNSC, LUAD and STAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .011). Together, the overview and detailed table identify HNSC as the clearest survival context for SPTBN5 RNA expression.
This table summarizes SPTBN5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SPTBN5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPTBN5 shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, READ, CHOL and LUAD. The COAD box plot shows higher SPTBN5 RNA expression in tumor versus normal tissue (log2 FC = +1.054, t-test p < 0.001).
This table shows molecular features associated with SPTBN5 in patient tissues and cancer cell lines. In patient samples, SPTBN5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SPTBN5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
